Benzinga's M&A Chatter for Monday November 17, 2014

The following are the M&A deals, rumors and chatter circulating on Wall Street for Monday November 17, 2014:

:

Halliburton Company

and Baker Hughes Incorporated

confirmed Monday, that Halliburton will acquire all the outstanding shares of Baker Hughes in a stock and cash transaction valued at $78.62 per Baker Hughes share, for an equity value of $34.6 billion. The agreement has been unanimously approved by both companies' Boards of Directors and needs approval from the shareholders of both companies. The deal is expected to close in H2 of 2015. Baker Hughes shares gained 9% Monday, to close at $65.23, while Halliburton shares lost 10.5% to close at $49.23.

:

Actavis plc

and Allergan, Inc.

announced Monday, that Actavis will acquire Allergan for $129.22 in cash, plus 0.3683 Actavis shares for each share of Allergan common stock, for a total value of $66 billion, or $219 per Allergan share. The deal has been approved by the Boards of Directors of both companies and is subject to the approval of the shareholders of both companies. The deal must receive antitrust clearance in the U.S., the EU and certain other jurisdictions, and is expected to close in Q2 of 2015. Allergan closed Monday at $209.20, a gain of more than 5%. Actavis shares rose 1.71%, to close at $247.94.

:

Zoetis Inc.

announced Monday an agreement to acquire animal health assets from Abbott Laboratories

for a purchase price of $255 million. The deal is expected to close in Q1 of 2015. Bill Ackman's Pershing Square announced an 8.3% stake in Zoetis on November 12, and the company announced a shareholder rights plan or "poison pill" on November 14. Zoetis closed Monday at $44.23, a gain of 2.5%.